Skip to main content

Table 4 Drugs targeting inflammatory immune cells in the tumour microenvironment of solid tumours (excluding haematological cancers)

From: Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia

CT identifier

Drug

Method of action

Cancer

Approved/phase study

Targeting T lymphocytes

NCT01844505

Nivolumab

Anti-PD1

mMM

Phase 3

NCT01642004

Nivolumab

Anti-PD1

NSCLC

Phase 3

NCT01354431

Nivolumab

Anti-PD1

mRCC

Phase 2

NCT00094653

Ipilimumab

Anti-CTLA4

mMM

Approved

NCT00861614

Ipilimumab

Anti-CTLA4

PC

Phase 3

NCT01450761

Ipilimumab

Anti-CTLA4

SCLC

Phase 3

NCT01285609

Ipilimumab

Anti-CTLA4

NSCLC

Phase 3

NCT01693783

Ipilimumab

Anti-CTLA4

Cervical cancer

Phase 2

NCT01860430

Ipilimumab

Anti-CTLA4

HNSCC

Phase 1B

NCT00257205

CP-675,206

Anti-CTLA4

mMM

Phase 3

Blocking immune cell recruitment

NCT01346358

IMC-CS4

CSFR1 antagonist

Advanced tumours

Phase 1

NCT01316822

ARRY-382

CSFR1 antagonist

Advanced tumours

Phase 1

NCT01015560

MLN1202

Anti-CCR2

Bone metastases

Phase 1

NCT01032122

Rituximab

Anti-CD20

mMM

Phase 1

NCT01376713

Ofatumumab

Anti-CD20

mMM

Phase 2

NCT01456585

CP-870,893

Anti-CD40

mPC

Phase 2

NCT01103635

CP-870,893

Anti-CD40

mMM

Phase 1

NCT00607048

CP-870,893

Anti-CD40

Solid tumours

Phase 1

Reprogramming immune cells

NCT00169104

G-CSF

Sustained neutrophilia

mBC

Phase 1/2

NCT00014456

G-CSF

 

Solid tumours

Phase 1

NCT00070629

Promune

TLR9 agonist

NSCLC

Phase 2

NCT00043394

Promune

TLR9 agonist

BC

Phase 2

NCT00070642

Promune

TLR9 agonist

MM

Phase 2

NCT00043407

Promune

TLR9 agonist

RCC

Phase 1/2

NCT00292045

Promune

TLR9 agonist

PC

Phase 1

NCT00669292

Promune

TLR9 agonist

Esophageal cancer

Phase 1/2

Multiple

Vaccines (Multiple targets)

T-cell activation

Multiple cancers

 

TH2-- > TH1 reprogramming

NCT01642290

Anti-OX40

Anti-OX40

mBC

Phase 1/2

NCT01644968

Anti-OX40

Anti-OX40

Advanced cancer

Phase 1

NCT01689870

Anti-OX40

Anti-OX40

mMM

Phase 1/2

  1. For an indepth review of the current landscape of targeting chronic inflammation, see Coussens [9]. CT identifier is to clinicaltrials.gov.
  2. Abbreviations: mMM metastatic malignant melanoma, NSCLC non-small cell lung cancer, mRCC metastatic renal cell carcinoma, PC prostate cancer, SCLC small-cell lung cancer, HNSCC head-and-neck squamous cell cancer, mBC metastatic breast cancer.
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us